MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jaip.2022.05.041

Медицинская библиотека · The journal of allergy and clinical immunology. In practice · 2022

SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.

Papaioannou Andriana I, Fouka Evangelia, Tzanakis Nikolaos, Antoniou Katerina, Samitas Konstantinos, Zervas Eleftherios, Kostikas Konstantinos, Bartziokas Konstantinos, Porpodis Konstantinos, Papakosta Despoina, Tzouvelekis Argyris, Gerogianni Irini, Kotsiou Ourania, Makris Michael, Rovina Nikoletta, Vlachou Garyfallia, Markatos Miltiadis, Vittorakis Stelios, Katsoulis Konstantinos, Papanikolaou Ilias, Afthinos Andreas, Katsaounou Paraskevi, Steiropoulos Paschalis, Latsios Dimitrios, Dimakou Katerina, Koukidou Sofia, Hillas Georgios, Tryfon Stavros, Kallieri Maria, Georgopoulou Athina, Avarlis Pantelis, Bakakos Petros, Markopoulou Katerina, Gaki Eleni, Paspala Asimina, Kyriakaki Zacharoula, Gourgoulianis Konstantinos I, Papiris Spyridon, Loukides Stelios

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

At the beginning of the pandemic, there have been considerable concerns regarding coronavirus disease 2019 (COVID-19) severity and outcomes in patients with severe asthma treated with biologics.

OBJECTIVE

To prospectively observe a cohort of severe asthmatics treated with biologics for the risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and disease severity during the COVID-19 pandemic.

METHODS

Physicians from centers treating patients with severe asthma all over Greece provided demographic and medical data regarding their patients treated with biologics. Physicians were also asked to follow up patients during the pandemic and to perform a polymerase chain reaction test in case of a suspected SARS-Cov-2 infection.

RESULTS

Among the 591 severe asthmatics (63.5% female) included in the study, 219 (37.1%) were treated with omalizumab, 358 (60.6%) with mepolizumab, and 14 (2.4%) with benralizumab. In total, 26 patients (4.4%) had a confirmed SARS-CoV-2 infection, 9 (34.6%) of whom were admitted to the hospital because of severe COVID-19, and 1 required mechanical ventilation and died 19 days after admission. Of the 26 infected patients, 5 (19.2%) experienced asthma control deterioration, characterized as exacerbation that required treatment with systemic corticosteroids. The scheduled administration of the biological therapy was performed timely in all patients with the exception of 2, in whom it was postponed for 1 week according to their doctors' suggestion.

CONCLUSION

Our study confirms that despite the initial concerns, SARS-CoV-2 infection is not more common in asthmatics treated with biologics compared with the general population, whereas the use of biologic treatments for severe asthma during the COVID-19 pandemic does not seem to be related to adverse outcomes from severe COVID-19.

Для цитирования: Papaioannou Andriana I, Fouka Evangelia, Tzanakis Nikolaos, Antoniou Katerina, Samitas Konstantinos, Zervas Eleftherios, Kostikas Konstantinos, Bartziokas Konstantinos, Porpodis Konstantinos, Papakosta Despoina, Tzouvelekis Argyris, Gerogianni Irini, Kotsiou Ourania, Makris Michael, Rovina Nikoletta, Vlachou Garyfallia, Markatos Miltiadis, Vittorakis Stelios, Katsoulis Konstantinos, Papanikolaou Ilias, Afthinos Andreas, Katsaounou Paraskevi, Steiropoulos Paschalis, Latsios Dimitrios, Dimakou Katerina, Koukidou Sofia, Hillas Georgios, Tryfon Stavros, Kallieri Maria, Georgopoulou Athina, Avarlis Pantelis, Bakakos Petros, Markopoulou Katerina, Gaki Eleni, Paspala Asimina, Kyriakaki Zacharoula, Gourgoulianis Konstantinos I, Papiris Spyridon, Loukides Stelios. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics.. The journal of allergy and clinical immunology. In practice. 2022. DOI: 10.1016/j.jaip.2022.05.041.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.